Resistant starch (RS) has gained attention for its potential benefits in metabolic health, glycemic control, and obesity management. Studies have shown that RS types 1 and 2 significantly lower postprandial blood glucose and improve insulin response in patients with type 2 diabetes and prediabetes, highlighting its role in managing glycemic levels effectively (Frontiers in Nutrition, 2023).

High-amylose maize starch supplementation has also been found to improve markers of metabolic health, such as insulin sensitivity and lipid profiles, reinforcing RS’s benefits for individuals with metabolic syndrome (Journal of Clinical Endocrinology & Metabolism, 2022).

RS supplementation enhances beneficial gut bacteria, contributing to better gut microbiota composition and overall health outcomes (Gut Microbes, 2022). Additionally, RS consumption leads to reductions in body weight and fat mass in overweight and obese individuals, attributed to increased satiety and reduced caloric intake (Obesity Reviews, 2022).

However, a randomized crossover assessment of native banana starch and high-amylose maize starch concluded that these types did not significantly improve glycemic control or variability, suggesting a need for further research to understand RS’s mechanisms better (Nutrients, 2021).

In conclusion, RS shows promise for improving metabolic health, glycemic control, and weight management. Further research is needed to optimize RS supplementation strategies for various health outcomes.